Japan Molecular Imaging Market Size, Share, By Application (Oncology, Cardiovascular, Neurology, and Respiratory), and By End Use (Hospitals, Diagnostic Imaging Centers, Research Institutes & Academic Centers), Japan Molecular Imaging Market Insights, Industry Trend, Forecasts to 2035

Japan Molecular Imaging Market Insights Forecasts to 2035

• Japan Molecular Imaging Market Size 2024: USD 301.6 Mn
• Japan Molecular Imaging Market Size 2035: USD 603.9 Mn
• Japan Molecular Imaging Market CAGR: 6.5%
• Japan Molecular Imaging Market Segments: Application and End Use

The growth of the Japanese molecular imaging market is consistent, backed by a strong healthcare system and the rising need for prompt and precise disease diagnosis. The use of PET, SPECT, and hybrid imaging systems is quite common in oncology, cardiology, neurology, and respiratory applications, with oncology being a significant factor in the growth, as Japan has a high cancer rate and an elderly population.

Government policies are the most powerful contributors that support market growth through the promotion of precision medicine and advanced diagnostic care. National healthcare programs, reimbursement coverage for molecular imaging procedures, and funding for oncology and nuclear medicine research are conducive to the adoption of technology while maintaining the highest standards of safety and quality.

Technological advancements have, moreover, been the leading factor pushing the market to growth. The innovations in digital PET scanners, AI algorithms used for image analysis, hybrid imaging, and advanced radiopharmaceuticals have positively impacted the imaging accuracy, scan duration, and workflow efficiency. Besides these developments, along with support from the policies, Japan's molecular imaging market is set for a bright future.

Market Dynamics of the Japan Molecular Imaging Market:

The increasing prevalence of cancer and neurological disorders, an aging population, and the demand for early and accurate disease diagnosis are the main factors that drive the Japan molecular imaging market. Moreover, the adoption of advanced imaging technologies like PET, SPECT, and hybrid systems is on the rise, and there is strong government support for precision medicine and cancer research, all of which contribute to the growth of the market. Besides, the remarkable developments in technology that enhance image quality and diagnostic precision are also important reasons for the market growth.

High price of molecular imaging devices, costs incurred for maintenance, and the requirement of having specialized infrastructure, along with skilled personnel. Moreover, the strict regulations for radiopharmaceuticals and safety from radiation may delay the use of such technologies in small health care establishments.

The developments in AI-assisted imaging, digital detectors, and new radiopharmaceuticals have opened up considerable avenues, in addition to the growing uses in tailor-made treatment and early diagnosis of diseases.

Market Segmentation

Japan's Molecular Imaging Market share is classified into Application and End Use.

By Application:

The Japan molecular imaging market is divided by application into oncology, cardiovascular, neurology, and respiratory. Among these, the oncology segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. This dominance is driven by a large number of cancer cases, the early diagnosis and treatment monitoring through the use of advanced imaging systems such as PET, SPECT, and hybrid modalities, and the government’s extensive support for cancer research and precision medicine initiatives.

By End Use:

The Japanese molecular imaging market is classified by end use into hospitals, diagnostic imaging centers, research institutes & academic centers. Among these, the hospital segment accounts for the largest market share and is expected to grow at a considerable CAGR during the period. A high number of patients and the availability of sophisticated molecular imaging facilities. It is also supported by the ongoing application of PET, SPECT, and hybrid systems in the regular diagnostics of oncology, cardiology, and neurology. Moreover, government backing, along with increased awareness of early diagnosis and precision medicine, are the factors that amplify the segment's growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Japan molecular imaging market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in Japan Molecular Imaging:

• GE HealthCare
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Shimadzu Corporation
• United Imaging Healthcare Co., Ltd.
• Bruker Corporation
• FUJIFILM Holdings Corporation
• Cubresa Inc.
• Other

Recent Developments in Japan Molecular Imaging:

• In March 2025, GE HealthCare Technologies Inc. finalized the purchase of Sumitomo Chemical's remaining 50% ownership in Nihon Medi-Physics Co., Ltd (NMP), thus turning the latter into a wholly owned subsidiary. This tactical action not only enhances GE HealthCare's role in the Japanese market for molecular imaging but also adds a variety of radiopharmaceuticals for PET and SPECT imaging through neuro-, cardio-, and onco- diagnostics across the whole area of the company's interests.

• In September 2025, there was a licensing agreement specifically for PYLARIFY between Lantheus Holdings, Inc., and GE HealthCare, only for Japan. According to the agreement, GE HealthCare will be the one to take care of the development, manufacturing, and commercialization of this prostate cancer PET imaging agent in Japan, which is a big step forward in PSMA-targeted molecular imaging for diagnosis and therapy monitoring of prostate cancer.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japanese molecular imaging market based on the following segments:

Japan Molecular Imaging Market, By Application

• Oncology
• Cardiovascular
• Neurology
• Respiratory

Japan Molecular Imaging Market, By End Use

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes & Academic Centers